NL-OMON46967已完成2 期
A phase I/II, open-label, uncontrolled, single-dose, dose-ascending, multi-centre trial investigating an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) administered to adult patients with severe or moderately severe haemophilia B - Phase I/II trial of AAV5-hFIX in severe or moderately severe haemophilia B
uniQure biopharma B.V.0 个研究点目标入组 8 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •2. Age * 18 years
- •3. Patients with congenital haemophilia B classified as one of the following:
- •- Known severe FIX deficiency with plasma FIX activity level <1% and a severe bleeding phenotype defined by one of the following:
- •o Currently on prophylactic FIX replacement therapy for a history of bleeding
- •o Currently on on-demand FIX replacement therapy with a current or past history of frequent bleeding defined as four or more bleeding episodes in the last 12 months or chronic haemophilic arthropathy (pain, joint destruction, and loss of range of motion) in one or more joints
- •- Known moderately severe FIX deficiency with plasma FIX activity level between * 1% and * 2% and a severe bleeding phenotype defined by one of the following:
- •o Currently on prophylactic FIX replacement therapy for a history of bleeding
- •o Currently on on-demand FIX replacement therapy with a current or past history of frequent bleeding defined as four or more bleeding episodes in the last 12 months or chronic haemophilic arthropathy (pain, joint destruction, and loss of range of motion) in one or more joints
- •4. More than 150 previous exposure days of treatment with FIX protein.
- •5. Acceptance to use a condom during sexual intercourse in the first three months after IMP administration or until AAV5 has been cleared from semen after a period of 75 days following IMP administration, as evidenced by the central laboratory from negative analysis results for at least 3 consecutively collected semen samples (this criterion is applicable also for subjects who are surgically sterilized)
- •6. Following receipt of verbal and written information about the trial, the subject has provided signed informed consent before any trial related activity is carried out.
排除标准
- •1. History of positive FIX inhibitor test
- •2. Positive FIX inhibitors test at Screening (measured by the local laboratory)
- •3. Neutralizing antibodies against AAV5 at Screening (measured by the central laboratory)
- •4. Screening laboratory values (measured by the central laboratory):
- •a. ALT > 2 times upper normal limit
- •b. AST > 2 times upper normal limit
- •c. total bilirubin > 2 times upper normal limit
- •d. ALP > 2 times upper normal limit
- •e. creatinine > 1.5 times upper normal limit
- •5. Positive HIV serological test at Screening, not controlled with anti-viral therapy as shown by CD4+ counts * 200 per µL or by a viral load of >200 copies per mL (measured by the central laboratory)
- •6. Active infection with Hepatitis B or C virus as reflected by Hepatitis B Surface Antigen (HBsAg), Hepatitis B extracellular Antigen (HBeAg), Hepatitis B Virus DeoxyriboNucleic Acid (HBV DNA) or Hepatitis C Virus RiboNucleic Acid (HCV RNA) positivity, respectively, at Screening (measured by the central laboratory).
- •7. History of Hepatitis B or C exposure, currently controlled by antiviral therapy
- •8. Any coagulation disorder other than haemophilia B
- •9. Thrombocytopenia, defined as a platelet count below 50 × 109 / L, at Screening (measured by the central laboratory)
- •10. Body mass index < 16 or * 35 kg/m2
- •11. Planned surgery for the initial 6 months after IMP administration in this trial
- •12. Previous arterial or venous thrombotic event (e.g. acute myocardial infarction, cerebrovascular disease and venous thrombosis)
- •13. Active severe infection or any other significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease, alcoholism, drug dependency or any other psychological disorder evaluated by the investigator to interfere with adherence to the protocol procedures or with the degree of tolerance to the IMP
- •14. Known significant medical condition including disseminated intravascular coagulation, fibrinolysis and liver fibrosis which, in the opinion of the investigator, may confound, contraindicate or limit the interpretation of either safety or efficacy data
- •15. Known history of an allergic reaction or anaphylaxis to FIX products
- •16. Known uncontrolled allergic conditions or allergy/hypersensitivity to any component of the IMP excipients
- •17. Previous gene therapy treatment
- •18. Receipt of an experimental agent within 60 days prior to Visit 1
- •19. Current participation or anticipated participation within one year after IMP administration in this trial in any other interventional clinical trial involving drugs or devices.
- •20. Clinical signs and/or symptoms of an active viral infection with a helper virus
研究者
相似试验
进行中（未招募）
1 期
A phase I/II trial investigating a gene therapy (AAV-hFIX) for the first time in humans, in adult patients with severe or moderately severe haemophilia B, to firstly evaluate its safety and identify side effects, and secondly evaluate if it is effectiveEUCTR2013-005579-42-DKuniQure biopharma B.V.12
进行中（未招募）
1 期
A phase I/II trial investigating a gene therapy (AAV-hFIX) for the first time in humans, in adult patients with severe or moderately severe haemophilia B, to firstly evaluate its safety and identify side effects, and secondly evaluate if it is effectiveEUCTR2013-005579-42-DEuniQure biopharma B.V.12
进行中（未招募）
1 期
A phase I/II trial investigating a gene therapy (AAV-hFIX) for the first time in humans, in adult patients with severe or moderately severe haemophilia B, to firstly evaluate its safety and identify side effects, and secondly evaluate if it is effectiveHaemophilia BMedDRA version: 18.0Level: LLTClassification code 10018939Term: Haemophilia B (Factor IX)System Organ Class: 100000004850EUCTR2013-005579-42-NLuniQure biopharma B.V.10
尚未招募
1 期
A Study of the Pharmacokinetics and Safety of a Single Dose of Lenabasum in Subjects with Hepatic Impairment Compared with Matched Healthy ControlsACTRN12620000712909Corbus Pharmaceuticals Inc32
进行中（未招募）
1 期
An early stage study looking at how much betrixaban gets into the blood of young people after they take a single capsule, and to see if it is safe to do so.Pediatric patients who are assessed to be at risk for Venous thromboembolism (VTE) but does not require immediate anticoagulant therapy, for example:a. Has previous thrombosis and completed a course of anti-coagulant therapy, and is considered to have a risk for recurrence of VTE, orb. Has any stable disease with a risk for arterial or venous thrombotic disorder, orc. Has any functional CVAD (Central Venous Access Device) in the upper or lower venous system.MedDRA version: 20.0Level: PTClassification code 10053468Term: Anticoagulant therapySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-002562-40-GBPortola Pharma UK Ltd33